Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Covington
Daiichi Sankyo
Cerilliant
Express Scripts
AstraZeneca
Merck
Dow
US Department of Justice

Generated: November 17, 2018

DrugPatentWatch Database Preview

Trastuzumab - Biologic Drug Details

« Back to Dashboard

Summary for trastuzumab
Tradenames:1
Patents:740
Applicants:1
BLAs:1
Suppliers: see list1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for trastuzumab
Pharmacology for trastuzumab
Mechanism of ActionHER2/Neu/cerbB2 Antagonists

US Patents for trastuzumab

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Try a Free Trial Novartis AG (Basel, CH) ➤ Try a Free Trial RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Try a Free Trial Array BioPharma Inc. (Boulder, CO) ➤ Try a Free Trial RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Try a Free Trial ACADEMIA SINICA (Taipei, TW) ➤ Try a Free Trial RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Try a Free Trial XUANZHU PHARMA CO., LTD. (Jinan, Shandong Province, CN) ➤ Try a Free Trial RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for trastuzumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
336 Luxembourg ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB EMTANSINE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES KADCYLA
2 Finland ➤ Try a Free Trial
2016000049 Germany ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
2016 00031 Denmark ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Chubb
UBS
Chinese Patent Office
Queensland Health
Daiichi Sankyo
Fish and Richardson
Johnson and Johnson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.